Cagrisema

As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making any guarantees.

Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish trends from a technical perspective.